London, Feb 9, 2026, 08:24 GMT — Trading during the regular session.
GSK edged up roughly 0.6% in early Monday action in London, with the stock hovering close to its 52-week peak. Shares hit 2,214 pence before settling at 2,211 by 0812 GMT.
GSK packs a punch on the FTSE 100, ranking among Europe’s largest publicly traded pharma groups. Any twitch in its share price ripples fast—index trackers and sector desks get the jolt right away.
No fresh trading update from the company on Monday. Investors sifted through a string of recent regulatory and policy headlines, looking for clues on what these might mean for sales trends and the company’s pricing muscle this year.
GSK announced Feb. 6 that the European Commission signed off on Nucala (mepolizumab) for adults with uncontrolled COPD who continue to have elevated blood eosinophils—a white blood cell tied to inflammation—even after using inhaled triple therapy (steroid plus two long-acting bronchodilators). “Patients will have the option for a monthly biologic shown to significantly reduce exacerbations,” said Kaivan Khavandi, GSK’s global head of respiratory R&D. gsk.com
Insiders made moves too. On Feb. 5, corporate development president David Redfern offloaded 100,000 shares at £21.09, according to a filing. The next day, Feb. 6, non-executive chair Jonathan Symonds picked up 2,500 shares at £21.14, a separate disclosure showed.
Drug pricing is back on the agenda in Washington. President Donald Trump rolled out TrumpRx.gov—a GoodRx-powered site offering drug discounts. Reuters reported GSK, along with Pfizer, AstraZeneca, Merck and others, had signed on to “most-favored nation” deals with the administration. Juliette Cubanski at KFF, who specializes in Medicare policy, questioned how much these efforts would actually benefit people holding insurance. Reuters
According to traders, that kind of aggressive discounting is a double-edged sword. Sure, it attracts additional cash-pay buyers. But it also tends to drag down the baseline in price negotiations and rebates—the key revenue zone for big pharma.
Still, with the stock trading so close to its yearly highs, there’s not much room for slips. Any drag in the COPD launch, or a tougher line on U.S. pricing, could quickly sap that potential upside.
Investors eye Feb. 19 as GSK’s ex-dividend date for its Q4 2025 payout. The record date lands on Feb. 20, with dividends scheduled for payment on April 9. Details are posted on gsk.com.
Related articles: Pharmaceuticals
